by Brenda Baletti, Ph.D. A “substantial proportion” of infants immunized against the RSV virus with the monoclonal antibody shot nirsevimab — marketed by Sanofi and AstraZeneca as Beyfortus — developed…
Posts tagged as “nirsevimab”
Advisors to the U.S. Food and Drug Administration on Thursday recommended approval of AstraZeneca’s new monoclonal antibody, which the drugmaker said is designed to protect…